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Hypothesis: Severe limb ischemia in patients having cardiac operations may 
occur after intraaortic balloon pump insertion, prolonged femoral vessel 
cannulation, percutaneous cardiopulmonary b pass, dissecting aneurysms, or 
emboli. Normal blood reperfusion can cause a postischemic syndrome that 
increases morbidity and mortality. This clinical study is based on an experi- 
mental infrastructure patterned after controlled cardiac reperfusion. (1) It 
tests the hypothesis that controlled limb reperfusion (i.e., modifying the 
composition of the initial reperfusate and the conditions of reperfusion) 
reduces the local and systemic omplications seen after normal blood reper- 
fusion. (2) It reports initial clinical application of this strategy in three cardiac 
surgery centers. Methods: Controlled limb reperfusion was applied to 19 
patients with signs of severe prolonged unilateral or bilateral ischemia 
(including paralysis, anesthesia, nd muscle contracture); six patients (32%) 
were  in cardiogenic shock. The mean ischemic duration was 26 -+ 6 hours. The 
reperfusion method indudes a 30-minute infusion into the distal vessels of  a 
normothermic reperfusate solution mixed with the patient's arterial blood 
(obtained proximal to the obstruction) in a 6:1 blood/reperfusate ratio. Data 
are mean - standard error of the mean. Results: Sixteen patients (84%) 
survived with salvaged and functional limbs at the time of discharge. No renal, 
cardiac, pulmonary, cerebral, or hemodynamic complications developed in the 
survivors. The three deaths occurred in patients undergoing controlled limb 
reperfusion while in profound postoperative cardiogenic shock; neither post- 
ischemic edema nor contracture developed in any of them. Conclusions: These 
findings show that controlled limb reperfusion can be applied readily with 
standard equipment that is used for cardiac surgery and may salvage limbs 
while reducing postreperfusion morbidity and mortality. (J THORAC CARDIO- 
VASC SURG 1996;111:873-81) 
I~evere  limb ischemia in patients having cardiac 
k Joperat ions  may occur after (1) transfemoral in- 
sertion of an intraaortic balloon pump (IABP), (2) 
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prolonged femoral vessel cannulation (i.e., thoracic 
aortic aneurysms, reoperations), (3) thoracoab- 
dominal acute aortic dissections, (4) prolonged per- 
cutaneous cardiopulmonary bypass, (5) thrombosis 
during or after removal of coronary angiography 
catheters into atherosclerotic vessels, or (6) throm- 
boembolization. 
Reperfusion of these severely ischemic limbs with 
normal blood may result in a postischemic syndrome 
that is associated with high mortality and morbidity 
rates. 1 The massive edema can increase fluid re- 
quirements and cause shock. Additionally, the wash- 
out of myoglobin, potassium, lactate, and micro- 
thrombi from the damaged skeletal muscle into the 
systemic circulation may cause renal failure, ar- 
rhythmias, shock, and eventually death, 1-3 inasmuch 
as mortality rates vary from 7.5% to 41%. 1'2 A 
postreperfusion syndrome may result in amputation 
or severe dysfunction in the salvaged limbs. 1' z Our 
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Table I. Composition of the asanguineous solution 
for the controlled limb reperfusate* (to be mixed 
with blood at a ratio of 6 to 1 ~) 
Amount 
Substance (ml) Principle 
Glucose 5% 500 Hyperosmolarity 
Substrate 
Citrate-phosphate-dextrose 150 Reduce Ca ++ 
Tromethamine 0.3 ml/L 200 Buffer 
Glutamate/aspartate 150 Substrate 
AllopurinoI 2.5 Free radical scavenger 
*Manufactured byDr. F. K6hler Chemie GmbH-H~hnlein, Germany. 
tSix parts blood and one part asanguineous solution. 
recent experimental studies 4-1° and those of oth- 
ers 1~-14 show that this injury can be reduced substan- 
tially by modifying the initial reperfusion phase 
during surgical revascularization of severely isch- 
emic skeletal muscle. The concept of controlled limb 
reperfusion 4-1° is based on principles described for 
cardiac reperfusion in patients with acute myocar- 
dial infarctions TM or after aortic clamping. 19-2~ 
This new application to ischemic skeletal muscle 
incorporates modifications of the conditions of 
reperfusion (temperature, pressure, and flow) and 
the composition of the reperfusate (oxygen tension, 
hematocrit value, free radical scavengers, osmolar- 
ity, calcium, pH, substrates, and glucose) during the 
first 30 minutes of regional revascularization. It also 
limits the local and systemic adverse effects of 
reperfusion after prolonged limb ischemia. 
The initial experience with clinical application of 
this method in 19 patients at three university cardiac 
surgical centers is summarized, and the results sug- 
gest that limb salvage is possible in extremities 
thought previously to be damaged irreversibly be- 
cause of ischemic contracture. 
Material and methods 
Patient population. Controlled limb reperfusion was 
performed in 19 patients with completely ischemic limbs 
at the Johann Wolfgang Goethe-University Frankfurt/M. 
(n = 15), Johannes Gutenberg-University Mainz (n = 3), 
and German Heart Center Berlin (n = 1). The design of 
the study was approved by the ethics committee. The 
onset of acute limb ischemia was defined as the time of 
pain as reported by the patient or the diagnosis made by 
the referring physician. Acute lower limb ischemia was 
confirmed by history, physical examination, and Doppler 
sonographic examination. Angiograms were not per- 
formed routinely in the preoperative period. 
Initial signs and symptoms, length of time from sudden 
occlusion to start of reperfusion, severity of ischemia, 
associated isease, source and location of thrombi or 
emboli, type of surgical intervention, and outcome of 
surgery were registered and are described in the Results 
section. 
Surgical technique for controlled limb reperfusion. 
Fluid, electrolytes, and cardiovascular bnormalities were 
corrected as much as possible before the operation. All 
patients received a standard heparin dose (300 IU/kg) 
after induction of general anesthesia. Central venous and 
urinary catheters were introduced, and blood pressure, 
heart rate, and electrocardiogram were monitored contin- 
uously. Fluid replacement was restricted to account for 
the crystalloid load infused with the controlled reperfu- 
sate, and furosemide (10 mg) was given intravenously, as 
needed. 
The common, superficial, and deep femoral arteries 
were exposed and isolated by a standard groin incision. A 
common femoral ongitudinal arteriotomy was made just 
above the bifurcation, and all thromboembolic material 
was removed from the iliac, superficial, and femoral 
arteries with a Fogarty catheter. The distal vessel was not 
irrigated. A wire-reinforced 22F cannula was inserted into 
the iliac artery via the same arteriotomy to aspirate 
autogenous oxygenated blood for subsequent admixture 
with the reperfusate solution (Table I). This cannula was 
connected to the blood line (Fig, 1) of the reperfusion set 
(HP Medica, Augsburg, Germany), which also contained 
a smaller caliber tubing for delivery of asanguineous 
solution. Both tubing lines were inserted into the head of 
a single roller pump, thereby permitting delivery of oxy- 
genated autogenous blood and reperfusate solution (Dr. 
F. K6hler Chemie GmbH, Alsbach-Hfihnlein, Germany) 
at a ratio of 6 to 1 (6 parts blood and I part asanguineous 
solution) to achieve the composition described in Table II. 
The lines were connected with a Y connector beyond 
the pump, and the modified blood reperfusate solution 
was channeled through a heat exchanger and an arterial 
filter. An additional Y connector was added to the deliv- 
ery line for connection of two reperfusion cannulas to be 
inserted into the superficial and deep femoral arteries. 
These vessels were each cannulated with a 10F dual- 
lumen catheter with self-inflating balloons (Research 
Medical Inc., Salt Lake City, Utah) to allow individual 
pressure measurement during reperfusion. The system 
was deaired before cannulation of the superficial and deep 
femoral arteries. Controlled reperfusion flow rate was 
adjusted by the roller pump at 150 to 250 ml/min. A tubing 
clamp on each perfusion line was used to change resis- 
tance, as needed, to ensure that intravascular pressure in 
each vessel never exceeded 60 mm Hg. 
Suturing of the venous patch with 5-0 monofilament 
suture to close the longitudinal arteriotomy was started 
during the 30-minute limb reperfusion interval. The can- 
hulas were then removed and the patch anastomosis 
completed to restore normal blood supply. Arterial sys- 
tolic pressure was kept below 120 mm Hg with systemic 
vasodilators within the first 24 hours after the operation. 
Systemic heparin was continued for 2 days to keep acti- 
vated clotting time at 150 seconds, and conversion to 
warfarin sodium was undertaken whenever a source of 
embolism (i.e., cardiac) was documented. 
Statistical analysis. Statistical analysis was done with 
the EPISTAT and the BIAS computer package provided 
by the Johann Wolfgang Goethe-University Frankfurt/ 
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Table II. Final composition of the controlled limb 
reperfusate (after mixing with blood in a ratio of 
6 to l )  
K + (mmol/L) 4.1 -+ 0.3 (3,4-5.1) 
Na + (mmol/L) 132 _+ 1 (130-135) 
Ca ++ (mmol/L) 0.32 +_ 0.04 (0.26-0.40) 
Glucose (mg/dL) 439 + 44 (335-560) 
Po2 (ram Hg) 147 _+ 18 (85-195) 
Pco 2 (mm Hg) 31.1 _+ 2.5 (24.6-37.6) 
pH 7.47 _+ 0.03 (7.37-7.55) 
Hemoglobin (gm/L) 8.4 +_ 0.3 (7.8-8.9) 
Osmolarity (mOsm/L) 335 _+ 12 (320-350) 
Data are mean--standard error of the mean (range). Po2, Oxygen 
tension; Pco2, carbon dioxide tension. 
Table III. Preoperative data (n = 19) 
Age (yr) 56 _+ 4 
Male/female 14/5 
Site of occlusion 
Infrarenal aorta 3/19 
Iliac artery 4/19 
Femoral artery 10/19 
Popliteal artery 2/19 
Complete/incomplete ischemia 18/1 
Cardiogenic shock 32% (6/19) 
Muscle contracture (thigh or shank) 53% (10/19) 
Duration of ischemia (hr) 26 -- 6 
Data are mean _+ standard error of the mean. 
M., Germany, in conjunction with Dr. H. Ackermann, a
biomathematician (Johann Wolfgang Goethe-University 
Frankfurt/M, Germany). Comparisons between groups 
were done with the one-way analysis of variance and 
nominal data by Fisher's exact est. Data are expressed as 
mean + standard error of the mean. Differences were 
considered significant at a p value less than 0.05. 
Results 
Preoperative data. Patients' ages ranged from 19 
to 83 years (Table III). Fourteen patients were male 
and five female. Of these, six patients (32%) were in 
cardiogenic shock requiring both inotropic support 
and intraaortic balloon counterpulsation. The fem- 
oral artery was the site of vascular occlusion in 16 
patients; three patients had acute infrarenal aortic 
occlusion with subsequent bilateral femoral artery 
occlusion. The mean ischemic interval averaged 26 
hours (range 6 to 39 hours). All limbs were pulse- 
less, pale, and paralyzed, and patients who were not 
intubated complained of pain and paresthesia. Mus- 
cle contracture of the thigh or shank occurred in 10 
of 19 patients (53%). The decision to offer con- 
trolled limb reperfusion was based on (1) clinical 
concern that severe postischemic syndrome would 
Fig. 1. Schematic representation f the clinical reperfu- 
sion set for controlled limb reperfusion. The iliac artery is 
cannulated to withdraw autogenous oxygenated blood 
from the patient. This blood is mixed with an asanguine- 
ous solution at a ratio of 6:1, administered atnormother- 
mia (37 ° C) through the heat exchanger, and delivered 
into the superficial and deep femoral arteries while in- 
traarterial pressures are being monitored. 
follow normal blood reperfusion r (2) the fear that 
primary amputation would be necessary because of 
contracture. 
Intraoperative data. The external i iac artery and 
the superficial and deep femoral arteries could be 
cannulated via the longitudinal arteriotomy after 
thrombectomy in 18 of 19 patients. Iliac artery 
thromboendarterectomy was needed in one patient 
to allow proximal cannulation. Systolic blood pres- 
sure fell slightly while the reperfusion system was 
primed with the patient's autologous oxygenated 
blood, and this was reversed after controlled reper- 
fusion was initiated. Systemic blood pressure, cen- 
tral venous pressure, systemic vascular resistance, 
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Table IV. Arteriovenous difference of electrolytes, glucose, Po2, Pco2, and pH dunng controlled limb 
reperfusion in patients 
Duration of controlled limb repelfusion 
1 min 5 rain 15 min 30 min 
Electrolytes 
K + (mmol/L)  0.2 _+ 0.8 -0 .6  _+ 0.1 -1 .2  _+ 0.1 -0 .9  +_ 0.3 
Na + (retool/L) -2  _+ 2 -3  -+ 1 -3  _+ 1 -3  + 1 
Ca ++ (retool/L) -0 .5  _+ 0.3 0.4 -+ 0.2 -0 .4  + 0.2 -0 .4  + 0.2 
Glucose (mg/dl) 74 _+ 37 143 + 66 165 _+ 59 186 -+ 53 
Blood gases 
Po 2 (ram Hg) 113 _+ 22 127 _+ 26 99 _+ 23 94 _+ 19 
Pco  2 (ram Hg) -16  _+ 4 -13  + 2 -18  -- 3 -13  + 3 
pH 0.12 _+ 0.02 0.06 + 0.05 0.14 _+ 0.02 0.11 + 0.02 
Data are mean _+ standard error of the mean. 
Table V. Maximal postoperative s rum values for 
enzymes, creatinine, blood urea nitrogen, and 
potassium 
Enzymes 
CK (U/L) 20,414 _+ 7,710 
AST (U/L) 455 _+ 184 
LDH (U/L) 1,356 _+ 540 
Renal  data 
creat inine (mg/dl) 2.4 _+ 0.7 
BUN (mg/dl) 65 + 8 
Electrolytes 
K + (mmol/L)  5.3 _+ 0.5 
Data are mean _+ standard error of the mean. CK, Creatine kinase; AST, 
aspartate aminotransferase; LDH, lactic dehydrogenase; BUN,, blood urea 
nitrogen; K +, potassium. 
heart rate, and urine output did not change, and 
each patient received approximately 800 ml of crys- 
talloid solution (range 214 to 1285 ml) as the 6:1 
blood/reperfusate solution was delivered. Reperfu- 
sion rates averaged 150 to 250 ml/min (range 50 to 
300 ml/min) to keep intravascular p essure between 
50 and 60 mm Hg. Normal arterial inflow was 
restored by vein patch closure of the arteriotomy 
after decannulation. 
Twelve of 19 patients underwent fasciotomy, 
which was performed prophylactically in the initial 
patients because severe limb edema was expected. 
Our early experience showed that most fasciotomies 
were unnecessary; therefore this was done subse- 
quently only if severe limb swelling followed revas- 
cularization. 
Intraoperative metabolic data (Table IV). Mini- 
mum and significant changes in serum, potassium, 
sodium, and calcium concentrations occurred uring 
the 30-minute period of controlled limb reperfusion, 
and severe hyperkalemia (>2 mEq/L increase in 
serum K +) never occurred. In contrast, glucose 
uptake rose progressively during the period of re- 
gional limb reperfusion, as arteriovenous glucose 
difference exceeded 140 mg/dl after 5 minutes. 
Substantial oxygen extraction occurred throughout 
the entire controlled reperfusion period, as arterio- 
venous oxygen difference ranged between 94 and 
127 mm Hg. Effluent femoral vein pH remained in 
the normal range of 7.3 to 7.4, even though carbon 
dioxide is released into the venous circulation. 
PostoPerative systemic alterations. Table V 
shows maximum values for serum, potassium, creat- 
inine, and blood urea nitrogen. Massive creatine 
kinase (CK) release occurred in all patients, but the 
increase in K +, creatinine, and blood urea nitrogen 
was negligible. The average postoperative fluid re- 
quirements were 30 ml/kg for the first 24 hours. 
Postoperative clinical data. Sixteen of 19 patients 
survived (84%), with deaths occurring in three of six 
patients undergoing controlled limb reperfusion 
during cardiogenic shock. No systemic postoperative 
complications occurred in survivors, inasmuch as 
none required hemodialysis, had rhythm disturbances, 
or had lung changes. All fasciotomies but one were 
closed between the fourth and eighth postoperative 
days. Each of the 16 survivors had full sensory and 
motor functional recovery of both limbs at the time of 
discharge as assessed by the discharging surgeon. 
Only one death was associated with the reperfu- 
sion process. Progressive congestive heart failure 
and multisystem organ failure developed ina patient 
with cardiogenic shock who had acute distal aortic 
occlusion. A second death was due to irreversible 
low output syndrome, and the third death was due to 
cerebral hypoxia nd sepsis in a patient who under- 
went acute coronary revascularization after arriving 
in the operating room while undergoing cardiopul- 
monary resuscitation. 
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Table VI. Clinical results after thromboembolectomy for acute arterial occlusion in 2392 patients 
No. of Mortality Amputation Nonfunctional 
Reference patients Ischemic time (%) (%) (%) Mean age 
1 17 1 hr-7 days 11.8 23.5 17.6 59 yr 
53 94 1-21 days 13.7 5.4 No data 72.8 yr 
54 246 1 hr-42 days 29.7 5.3 9.8 62 yr 
55 142 1 hr-30 clays 28 9 No data No data 
56 224 No data 23.1 9 No data 63 yr 
57 118 No data 19.5 31 No data No data 
58 91 1 hr-8 days 34 11 No data 77 yr 
2 85 1 hr-7 days 41 40 No data No data 
59 124 1 hr-? 30 22 No data No data 
60 100 1 hr-30 days 26 10 No data 67 yr 
61 128 No data 34 5 No data 68 yr 
62 125 1 hr-24 hr 25.6 No data No data 
63 119 1 hr->8 days 27 18 No data No data 
64 142 i hr->24 hr 27 8.5 No data 65.5 yr 
65 66 1 hr->24 hr 34.8 6.1 No data No data 
66 65 1 hr->12 hr 48 12 No data No data 
67 122 1 hr-48 hr 10.6 11.5 8 No data 
68 221 No data 37 27 No data 77 yr 
69 163 No data 14.7 8 16 62.5 yr 
Discussion 
Limb ischemia in patients who have had cardiac 
operations i  an infrequent but life-threatening com- 
plication that occurs most commonly after pro- 
longed transfemoral intraaortic balloon counterpul- 
sation. The reported prevalence varies between 9% 
and 12%, 22-27 and amputation is needed in 1% of 
patients. 2sLimb ischemia fter insertion of an IABP 
is due to either flow obstruction by the cannula or 
mechanical vessel wall trauma during insertion and 
is accentuated by the intense vasoconstriction that 
accompanies the low cardiac output in these pa- 
tients. 29-31 Ischemic limb complications are more 
common in patients with preexisting arterial occlu- 
sive disease, 32 in women 33'34 because of their 
smaller caliber vessels, and in patients in whom 
larger IABP catheters are usedY Recommended 
prophylactic measures include transaortic IABP in- 
sertion,36, 37 use of shunt sheaths with side holes, 38 
sheathless IABP insertion, 39' 40 iliac artery balloon 
angioplasty if the vessel is stenotic, 41 and papaverine 
treatment. 42 Unfortunately, limb ischemia remains 
the major complication after transfemoral IABP 
insertion despite these efforts. Additional causes of 
limb ischemia include acute dissecting aneurysms, 
presence of aortoiliac disease in patients who un- 
dergo percutaneous femoral arterial cannulation for 
instituting cardiopulmonary b pass for emergency 
cardiac operations, 43' 44 or circulatory support dur- 
ing angioplasty. 45 
The mortality rate after primary amputation for 
acute limb ischemia is approximately 1%, whereas 
mortality increases to approximately 20% to 30% 
(range 10.6% to 48%) after evascularization (Table 
VI). Reperfusion i jury of tissue jeopardized by the 
preceding ischemic period is the principal cause for 
increased morbidity and mortality after acute limb 
revascularization) '4 Skeletal muscle has been 
shown to be relatively intact biochemically and 
structurally even after prolonged periods of isch- 
emia,6, 46 yet several experimental nd clinical re- 
ports indicate that sudden restoration of normal 
blood flow supply may cause severe dema, rhabdo- 
myolysis, and leakage of myocyte content into the 
plasma. 46-48 The resultant massive washout of lac- 
tate, potassium, and myoglobin may produce life- 
threatening myoglobinuric renal failure, hyperkale- 
mia, disseminated intravascular coagulation, and 
acute cardiomyopathy. 1' 2, 49 
We 4-1° have demonstrated xperimentally that local 
and systemic omplications after normal blood reper- 
fusion can be reduced significantly if the vulnerable 
skeletal muscle is managed uring the first 30 minutes 
of restoration ofits blood supply by the controlled limb 
reperfusion strategy. Using a model of acute infrarenal 
aortic occlusion for 6 hours, we 6' 10 developed evidence 
that uncontrolled normal blood reperfusion produced 
by suddenly releasing the aortic occlusion reduced 
oxygen consumption, produced marked edema and 
massive CK and potassium release, and increased 
vascular esistance severely, causing low reflow. The 
result was decreased recovery of range of motion of 
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the knee joint. Biopsy of the jeopardized muscle 
before reperfusion and evaluation of the tissue with an 
electron microscope showed structural integrity, 6 and 
this observation emphasized the importance of devel- 
oping a reperfusion method that could limit injury to 
skeletal muscle jeopardized by ischemia otherwise 
destined for necrosis. These adverse ffects of normal 
blood reperfusion were relatively comparable with 
those after normal blood reperfusion i  ischemic ar- 
diac myocytes. Our management strategy is based on 
the salutary effects hown when controlled reperfusion 
was provided to cardiac muscle after regional and 
global ischemia. 15-18 
The severe damage produced by normal blood 
reperfusion could be reduced substantially when the 
conditions of reperfusion and the composition of 
the reperfusate were controlled for 30 minutes in a 
fashion somewhat similar to that applied to region- 
ally ischemic cardiac muscle. 15q8 The controlled 
limb reperfusion phase restored oxygen consump- 
tion to control evels, avoided tissue edema, limited 
CK and potassium release significantly, decreased 
vascular resistance, restored limb flow to greater 
than control values, and restored a normal range of 
motion to the knee joint. 4' 7, 8 
The findings of the safety and superiority of 
controlled limb reperfusion led to the current appli- 
cation of these principles in 19 patients with pro- 
longed severe ischemia veraging 26 + 6 hours: The 
treatment protocol was used despite the presence of 
ischemic muscle contracture in 53% of patients. The 
reversal of ischemic contracture is, to our knowl- 
edge, a new finding that irreversible damage has not 
yet occurred despite the clinical sign of extensive 
ischemic damage. The only deaths occurred in three 
of six patients who were in profound cardiogenic 
shock before the operation (16% mortality). Sixteen 
of 19 patients (84%) were discharged with salvaged 
limbs, and renal, pulmonary, and cardiac complica- 
tions did not occur. 
No randomization was applied to the patient 
cohort undergoing controlled limb reperfusion (1) 
because the experimental data in both crystalloid 4-9 
and blood-perfused models 1° showed significant im- 
provement of skeletal muscle viability as compared 
with that obtained with unmodified reperfusion and 
(2) because of our successful preliminary clinical 
experience with this technique. 5°
Reperfused skeletal muscle exhibited active oxygen 
and glucose uptake (see Table IV). We interpret these 
findings as evidence of active cellular repair during the 
initial controlled reperfusion phase, which restores 
some of the cellular hemostatic mechanisms that ren- 
der jeopardized skeletal muscle able to cope with the 
subsequent normal blood reperfusion. The marked 
washout of CK (see Table V) reflects the severe 
ischemic insult to the skeletal muscle, yet the recovery 
of function indicates that extensive necrosis had not 
yet occurred. However, because the sensory and motor 
functional recovery was not assessed by neurologists, it
is possible that some slight alterations might not have 
been recognized by the discharging physician. Our 
finding of high CK values and functional recovery of 
the skeletal muscle is paralleled by reports in cardiac 
muscle where the mode of reperfusion had no effect 
on the CK-MB values, whereas a significantly better 
recovery of regional wall motion could be achieved by 
an initial treatment of the previously ischemic myocar- 
dium during the initial reperfusion phase. 16-18 Never- 
theless, it is likely that the massive release of the 
large-molecule CK will indicate some cellular death. 
Additionally, no renal impairment was detected in 
surviving patients, and slight hyperkalemia did not 
cause cardiac rhythm disturbances. 
The surgical technique applied technology used 
routinely for delivery of cardioplegic solutions during 
operations--a heat exchanger, tubing of different cal- 
iber to fix the blood/reperfusate ratio, and method of 
monitoring reperfusion pressure. The 6:1 ratio (blood/ 
crystalloid solution) was used to limit fluid overload 
attendant with the crystalloid component of the reper- 
fusate solution, especially in patients with congestive 
heart failure or cardiogenic shock. Priming of the 
current system included withdrawal of 400 ml of 
autogenous blood from the patient, causing slight 
hypotension. This was reversed readily after controlled 
limb reperfusion was initiated, and this volume was 
returned to the patient ogether with the crystalloid 
solution. The total volume of reperfusate was approx- 
imately 6 L (200 ml/min in 30 minutes), but the 
crystalloid component was limited to 800 ml by the 6:1 
blood/reperfusate ratio. This crystalloid infusion did 
not produce signs of hypervolemia. Future reperfu- 
sates will likely include higher ratios of blood to 
crystalloid solution to reduce the volume of crystalloid 
solution further. 
The reperfusate composition differs slightly from 
the cardiac reperfusate on which it is based, and which 
is diluted by the volume of the extracorporeal circuit 
during cardiac surgery. Modifications were made to 
limit potential adverse systemic effects, because the 
diluent returns to the patient by way of the femoral 
vein. For these reasons, we reduce the volume of 
tromethamine buffer to decrease the tendency for 
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systemic alkalosis, decrease the amount of citrate- 
phosphate-dextrose to limit the propensity for systemic 
hypocalcemia, nd lower the concentration of gluta- 
mate and aspartate, because amino acids may be 
associated with systemic vasodilatation. 51 
The selected antioxidant was allopurinol because 
of its availability and reported use in patients with 
cardiac disease. 52 Other antioxidants, especially 
those having those site-directed effects, may be used 
subsequently (i.e., superoxide dismutase, catalase, 
and deferoxamine). We suspect also that subsequent 
protocols will include interventions that alter other 
aspects of reperfusion injury. These protocols may 
incorporate mechanisms of decreasing leukocytes or 
their adherence and modifications of endothelial 
function (i.e., L-arginine or nitric oxide) as more is 
learned about reperfusion injury. 
Controlled reperfusate strategy was straightfor- 
ward and simple to establish in patients requiring 
cardiac operations, inasmuch as similar principles 
are used for blood cardioplegic delivery during 
myocardial protection. Cardiac surgeons and perfu- 
sionists are familiar with these principles of organ 
protection. This study was restricted to patients with 
impending limb loss as a result of prolonged isch- 
emia. We suspect that future applications may in- 
clude the prophylactic use of controlled limb reper- 
fusion with prolonged ischemia (>3 hours after 
femoral vessel cannulation), as well as for extremi- 
ties exhibiting signs of ischemia during prolonged 
use of an IABP. 
We conclude that clinical application of an exper- 
imentally based strategy of controlled limb reperfu- 
sion is feasible and useful in the setting of acute limb 
ischemia in patients having cardiac operations. Its 
feasibility is enhanced by the fact that the tools for 
its application are present during most cardiac pro- 
cedures in which blood cardioplegia is used (i.e., 
heat exchanger, differential tubing sets, reperfusion 
cannulas). The encouraging early results in patients 
with profound ischemia (averaging 26 hours, includ- 
ing contracture) may lead to the prophylactic use of 
revascularization after prolonged femoral vessel 
cannulation and limit postreperfusion syndrome fur- 
ther. We hope this report stimulates others to test 
the applicability of controlled reperfusion in limbs 
otherwise destined for severe damage. Reproduc- 
tion of our results by others should decrease the 
prevalence of postischemic syndrome after acute 
limb ischemia in patients having cardiac operations, 
as well as in other patients at risk for this devastating 
complication of revascularization. 
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